Advertisement
Canada markets close in 2 hours 1 minute
  • S&P/TSX

    22,040.30
    +168.34 (+0.77%)
     
  • S&P 500

    5,075.08
    +64.48 (+1.29%)
     
  • DOW

    38,529.96
    +289.98 (+0.76%)
     
  • CAD/USD

    0.7323
    +0.0022 (+0.30%)
     
  • CRUDE OIL

    83.12
    +1.22 (+1.49%)
     
  • Bitcoin CAD

    91,218.09
    +140.20 (+0.15%)
     
  • CMC Crypto 200

    1,436.89
    +22.13 (+1.56%)
     
  • GOLD FUTURES

    2,340.30
    -6.10 (-0.26%)
     
  • RUSSELL 2000

    2,007.38
    +39.91 (+2.03%)
     
  • 10-Yr Bond

    4.5900
    -0.0330 (-0.71%)
     
  • NASDAQ

    15,716.71
    +265.40 (+1.72%)
     
  • VOLATILITY

    15.97
    -0.97 (-5.72%)
     
  • FTSE

    8,044.81
    +20.94 (+0.26%)
     
  • NIKKEI 225

    37,552.16
    +113.55 (+0.30%)
     
  • CAD/EUR

    0.6836
    -0.0014 (-0.20%)
     

SAGE Therapeutics’ GABA Receptor–Based Portfolio

SAGE Therapeutics’ GABA Receptor–Based Portfolio

As we discussed earlier, SAGE Therapeutics’ (SAGE) portfolio includes the products it has under development for the treatment of life-threatening central nervous system disorders based on either GABA (gamma-Aminobutyric acid) or NMDA (N-methyl-D-aspartate) receptor systems.